Cargando…

Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases

INTRODUCTION: Tumor-related liver failure (TRLF) is the most common cause of death in patients with intrahepatic cholangiocarcinoma (ICC). Though we previously showed that liver radiotherapy (L-RT) for locally advanced ICC is associated with less frequent TRLF and longer overall survival (OS), the r...

Descripción completa

Detalles Bibliográficos
Autores principales: De, Brian, Upadhyay, Rituraj, Liao, Kaiping, Kumala, Tiffany, Shi, Christopher, Dodoo, Grace, Abi Jaoude, Joseph, Corrigan, Kelsey L., Manzar, Gohar S., Marqueen, Kathryn E., Bernard, Vincent, Lee, Sunyoung S., Raghav, Kanwal P.S., Vauthey, Jean-Nicolas, Tzeng, Ching-Wei D., Tran Cao, Hop S., Lee, Grace, Wo, Jennifer Y., Hong, Theodore S., Crane, Christopher H., Minsky, Bruce D., Smith, Grace L., Holliday, Emma B., Taniguchi, Cullen M., Koong, Albert C., Das, Prajnan, Javle, Milind, Ludmir, Ethan B., Koay, Eugene J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427952/
https://www.ncbi.nlm.nih.gov/pubmed/37593365
http://dx.doi.org/10.1159/000530134
_version_ 1785090357916073984
author De, Brian
Upadhyay, Rituraj
Liao, Kaiping
Kumala, Tiffany
Shi, Christopher
Dodoo, Grace
Abi Jaoude, Joseph
Corrigan, Kelsey L.
Manzar, Gohar S.
Marqueen, Kathryn E.
Bernard, Vincent
Lee, Sunyoung S.
Raghav, Kanwal P.S.
Vauthey, Jean-Nicolas
Tzeng, Ching-Wei D.
Tran Cao, Hop S.
Lee, Grace
Wo, Jennifer Y.
Hong, Theodore S.
Crane, Christopher H.
Minsky, Bruce D.
Smith, Grace L.
Holliday, Emma B.
Taniguchi, Cullen M.
Koong, Albert C.
Das, Prajnan
Javle, Milind
Ludmir, Ethan B.
Koay, Eugene J.
author_facet De, Brian
Upadhyay, Rituraj
Liao, Kaiping
Kumala, Tiffany
Shi, Christopher
Dodoo, Grace
Abi Jaoude, Joseph
Corrigan, Kelsey L.
Manzar, Gohar S.
Marqueen, Kathryn E.
Bernard, Vincent
Lee, Sunyoung S.
Raghav, Kanwal P.S.
Vauthey, Jean-Nicolas
Tzeng, Ching-Wei D.
Tran Cao, Hop S.
Lee, Grace
Wo, Jennifer Y.
Hong, Theodore S.
Crane, Christopher H.
Minsky, Bruce D.
Smith, Grace L.
Holliday, Emma B.
Taniguchi, Cullen M.
Koong, Albert C.
Das, Prajnan
Javle, Milind
Ludmir, Ethan B.
Koay, Eugene J.
author_sort De, Brian
collection PubMed
description INTRODUCTION: Tumor-related liver failure (TRLF) is the most common cause of death in patients with intrahepatic cholangiocarcinoma (ICC). Though we previously showed that liver radiotherapy (L-RT) for locally advanced ICC is associated with less frequent TRLF and longer overall survival (OS), the role of L-RT for patients with extrahepatic metastatic disease (M1) remains undefined. We sought to compare outcomes for M1 ICC patients treated with and without L-RT. METHODS: We reviewed ICC patients that found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT, matching them with an institutional cohort by propensity score and a National Cancer Database (NCDB) cohort by frequency technique. The median biologically effective dose was 97.5 Gy (interquartile range 80.5–97.9 Gy) for L-RT. Patients treated with other local therapies or supportive care alone were excluded. We analyzed survival with Cox proportional hazard modeling. RESULTS: We identified 61 patients who received L-RT and 220 who received chemotherapy alone. At median follow-up of 11 months after diagnosis, median OS was 9 months (95% confidence interval [CI] 8–11) and 21 months (CI: 17–26) for patients receiving chemotherapy alone and L-RT, respectively. TRLF was the cause of death more often in the patients who received chemotherapy alone compared to those who received L-RT (82% vs. 47%; p = 0.001). On multivariable propensity score-matched analysis, associations with lower risk of death included duration of upfront chemotherapy (hazard ratio [HR] 0.82; p = 0.005) and receipt of L-RT (HR: 0.40; p = 0.002). The median OS from diagnosis for NCDB chemotherapy alone cohort was shorter than that of the institutional L-RT cohort (9 vs. 22 months; p < 0.001). CONCLUSION: For M1 ICC, L-RT associated with a lower rate of death due to TRLF and longer OS versus those treated with chemotherapy alone. Prospective studies of L-RT in this setting are warranted.
format Online
Article
Text
id pubmed-10427952
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-104279522023-08-17 Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases De, Brian Upadhyay, Rituraj Liao, Kaiping Kumala, Tiffany Shi, Christopher Dodoo, Grace Abi Jaoude, Joseph Corrigan, Kelsey L. Manzar, Gohar S. Marqueen, Kathryn E. Bernard, Vincent Lee, Sunyoung S. Raghav, Kanwal P.S. Vauthey, Jean-Nicolas Tzeng, Ching-Wei D. Tran Cao, Hop S. Lee, Grace Wo, Jennifer Y. Hong, Theodore S. Crane, Christopher H. Minsky, Bruce D. Smith, Grace L. Holliday, Emma B. Taniguchi, Cullen M. Koong, Albert C. Das, Prajnan Javle, Milind Ludmir, Ethan B. Koay, Eugene J. Liver Cancer Research Article INTRODUCTION: Tumor-related liver failure (TRLF) is the most common cause of death in patients with intrahepatic cholangiocarcinoma (ICC). Though we previously showed that liver radiotherapy (L-RT) for locally advanced ICC is associated with less frequent TRLF and longer overall survival (OS), the role of L-RT for patients with extrahepatic metastatic disease (M1) remains undefined. We sought to compare outcomes for M1 ICC patients treated with and without L-RT. METHODS: We reviewed ICC patients that found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT, matching them with an institutional cohort by propensity score and a National Cancer Database (NCDB) cohort by frequency technique. The median biologically effective dose was 97.5 Gy (interquartile range 80.5–97.9 Gy) for L-RT. Patients treated with other local therapies or supportive care alone were excluded. We analyzed survival with Cox proportional hazard modeling. RESULTS: We identified 61 patients who received L-RT and 220 who received chemotherapy alone. At median follow-up of 11 months after diagnosis, median OS was 9 months (95% confidence interval [CI] 8–11) and 21 months (CI: 17–26) for patients receiving chemotherapy alone and L-RT, respectively. TRLF was the cause of death more often in the patients who received chemotherapy alone compared to those who received L-RT (82% vs. 47%; p = 0.001). On multivariable propensity score-matched analysis, associations with lower risk of death included duration of upfront chemotherapy (hazard ratio [HR] 0.82; p = 0.005) and receipt of L-RT (HR: 0.40; p = 0.002). The median OS from diagnosis for NCDB chemotherapy alone cohort was shorter than that of the institutional L-RT cohort (9 vs. 22 months; p < 0.001). CONCLUSION: For M1 ICC, L-RT associated with a lower rate of death due to TRLF and longer OS versus those treated with chemotherapy alone. Prospective studies of L-RT in this setting are warranted. S. Karger AG 2023-03-16 /pmc/articles/PMC10427952/ /pubmed/37593365 http://dx.doi.org/10.1159/000530134 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Research Article
De, Brian
Upadhyay, Rituraj
Liao, Kaiping
Kumala, Tiffany
Shi, Christopher
Dodoo, Grace
Abi Jaoude, Joseph
Corrigan, Kelsey L.
Manzar, Gohar S.
Marqueen, Kathryn E.
Bernard, Vincent
Lee, Sunyoung S.
Raghav, Kanwal P.S.
Vauthey, Jean-Nicolas
Tzeng, Ching-Wei D.
Tran Cao, Hop S.
Lee, Grace
Wo, Jennifer Y.
Hong, Theodore S.
Crane, Christopher H.
Minsky, Bruce D.
Smith, Grace L.
Holliday, Emma B.
Taniguchi, Cullen M.
Koong, Albert C.
Das, Prajnan
Javle, Milind
Ludmir, Ethan B.
Koay, Eugene J.
Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases
title Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases
title_full Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases
title_fullStr Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases
title_full_unstemmed Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases
title_short Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases
title_sort definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427952/
https://www.ncbi.nlm.nih.gov/pubmed/37593365
http://dx.doi.org/10.1159/000530134
work_keys_str_mv AT debrian definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT upadhyayrituraj definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT liaokaiping definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT kumalatiffany definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT shichristopher definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT dodoograce definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT abijaoudejoseph definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT corrigankelseyl definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT manzargohars definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT marqueenkathryne definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT bernardvincent definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT leesunyoungs definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT raghavkanwalps definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT vautheyjeannicolas definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT tzengchingweid definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT trancaohops definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT leegrace definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT wojennifery definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT hongtheodores definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT cranechristopherh definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT minskybruced definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT smithgracel definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT hollidayemmab definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT taniguchicullenm definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT koongalbertc definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT dasprajnan definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT javlemilind definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT ludmirethanb definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases
AT koayeugenej definitiveliverradiotherapyforintrahepaticcholangiocarcinomawithextrahepaticmetastases